The available studies have a relatively short duration, making it difficult to assess the long-term efficacy and safety of SGLT2 inhibitors and pioglitazone in NAFLD or NASH treatment. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.